Abbott (NYSE:ABT) announced today that it received FDA approval for its Epic Plus and Epic Plus Supra stented tissue valves.
The approval offers improved therapy options for people with aortic or mitral valve disease through the next-generation devices that build off of Abbott’s Epic surgical valve platform, according to a news release.
Epic Plus, a bioprosthetic valve, does not require the long-term use of blood-thinner medication, making them the recommended option for those who can’t take blood thinners or those over 70 years of age (a group with an increased bleeding risk from such medicines).
Abbott enhanced the Epic Plus platform with more radiopaque markers to make it easier for doctors to navigate if future transcatheter procedures are needed. The new valves’ creators designed them to deliver long-term performance and durability with Abbott’s unique anticalcification technology.
The Epic Plus mitral holder helps to ensure the precise insertion of the valve, according to Abbott. It has a lower profile so physicians can better view the device for accurate placement during implantation. It’s possible to implant the device in the aortic or mitral valve position and those with more complicated anatomies.
“Whether it’s developing new treatment options or improving upon our existing proven therapies, Abbott is constantly striving to deliver innovative solutions to address life-threatening heart conditions,” SVP of Abbott’s structural heart business Michael Dale said in the release. “This FDA approval affirms our commitment to advancement of the Epic Platform and our mission to help people live better lives through better health.”